[FOLD] Amicus Therapeutics, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 4.99 Change: 0.46 (10.15%)
Ext. hours: Change: 0 (0%)

chart FOLD

Refresh chart

Strongest Trends Summary For FOLD

FOLD is in the medium-term down -30% in 1 year.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases. It develops enzyme replacement therapies (ERTs) for lysosomal storage disorders (LSDs), including Fabry disease, Pompe disease, and Mucopolysaccharoidosis Type I (MPS I). The company also develops novel small molecules as monotherapy treatments for Fabry disease and Parkinson's disease. Its chaperone-advanced replacement therapy program is used to develop next-generation ERTs by co-formulating therapeutic enzymes with proprietary pharmacological chaperones. The company?s lead programs include the small molecule pharmacological chaperones, migalastat HCl as a monotherapy that is in Phase III global registration studies for Fabry patients with genetic mutations; and AT2220 (duvoglustat HCl), which has completed Phase II safety used for the treatment of Pompe disease. Its products also comprise AT-B200, a proprietary recombinant human acid-alpha g

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-40.12% ROE-74.29% ROI-61.43%
Current Ratio7.19 Quick Ratio Long Term Debt/Equity0.07 Debt Ratio0.2
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities4.06 M Cash From Investing Activities21.66 M Cash From Operating Activities-20.98 M Gross Profit
Net Profit-24.29 M Operating Profit-24.06 M Total Assets192.62 M Total Current Assets151.25 M
Total Current Liabilities21.02 M Total Debt14.4 M Total Liabilities88.61 M Total Revenue
Technical Data
High 52 week17.09 Low 52 week8.38 Last close11.44 Last change-5.22%
RSI43 Average true range0.58 Beta1.17 Volume3.52 M
Simple moving average 20 days-2.41% Simple moving average 50 days6.18% Simple moving average 200 days-12.66%
Performance Data
Performance Week0.88% Performance Month5.05% Performance Quart-3.87% Performance Half-19.38%
Performance Year-30.24% Performance Year-to-date19.42% Volatility daily3% Volatility weekly6.7%
Volatility monthly13.73% Volatility yearly47.55% Relative Volume222.44% Average Volume2.78 M
New High New Low


2019-03-20 07:00:00 | Amicus Therapeutics Issued Two U.S. Patents for Pompe Enzyme ATB200

2019-03-07 14:52:00 | Amicus Therapeutics Looks Impressive If it Can Rally Above $18

2019-03-06 14:39:58 | Will Amicus Therapeutics, Inc.’s NASDAQ:FOLD Earnings Grow In The Years Ahead?

2019-03-01 11:59:04 | Amicus FOLD Reports Wider-than-Expected-Loss for 2018

2019-02-28 14:39:52 | Edited Transcript of FOLD earnings conference call or presentation 28-Feb-19 1:30pm GMT

2019-02-28 12:04:47 | Amicus Therapeutics Inc FOLD Q4 2018 Earnings Conference Call Transcript

2019-02-28 07:00:00 | Amicus Therapeutics Announces Full-Year 2018 Financial Results and 2019 Corporate Updates

2019-02-28 06:30:00 | Amicus Therapeutics, Inc. to Host Earnings Call

2019-02-26 07:32:04 | N.J. biotech firm expanding to Philadelphia, creating 200 new jobs

2019-02-26 07:00:00 | Amicus Establishes Global Research and Gene Therapy Center of Excellence in Philadelphia

2019-02-25 09:02:02 | What's in Store for Universal Health UHS Q4 Earnings?

2019-02-25 04:00:00 | U.S. FDA Grants Breakthrough Therapy Designation “BTD” to Amicus’ AT-GAA in Late Onset Pompe Disease

2019-02-22 16:36:09 | What's in Store for Teladoc's TDOC Q4 Earnings?

2019-02-21 10:31:03 | Amicus Therapeutics FOLD Expected to Beat Earnings Estimates: Should You Buy?

2019-02-20 09:32:02 | Tenet Healthcare THC Q4 Earnings: What's in the Offing?

2019-02-13 07:30:00 | New Research Coverage Highlights Amicus Therapeutics, Clovis Oncology, YRC Worldwide, FORTERRA INC, Shenandoah Telecommunications, and Basic Energy Services — Consolidated Revenues, Company Growth, and Expectations for 2019

2019-02-12 07:00:00 | Amicus Therapeutics to Announce Full-Year 2018 Financial Results on February 28, 2019

2019-02-11 16:51:09 | Zoetis ZTS to Report Q4 Earnings: What's in the Cards?

2019-02-05 16:01:00 | Amicus Therapeutics Announces Positive data in Pompe Disease Phase 1/2 Study for Up to 24 Months at 15th Annual WORLDSymposium™

2019-02-04 10:38:00 | 2 Small-Cap Stocks That Are Still a Bargain

2019-01-28 08:00:00 | Today's Research Reports on Trending Tickers: Amicus Therapeutics and ACADIA Pharmaceuticals

2019-01-24 10:08:03 | Amicus FOLD Boasts Strong Pipeline Amid Stiff Competition

2019-01-18 07:00:00 | Amicus Therapeutics Announces Presentations and Posters at 15th Annual WORLDSymposium™ 2019

2019-01-16 08:05:00 | Today's Research Reports on Trending Tickers: Amicus Therapeutics and Sage Therapeutics

2019-01-15 09:00:00 | Is Amicus Therapeutics' Sharp Reversal Warranted?

2019-01-10 07:30:00 | Research Report Identifies FedEx, Amicus Therapeutics, National HealthCare, Allegion, Horizon Global, and PICO with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

2019-01-07 07:00:00 | Amicus Therapeutics Provides Full-Year 2019 Strategic Outlook and Financial Guidance

2019-01-03 16:01:00 | Amicus Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

2019-01-03 07:00:00 | Amicus Therapeutics Announces Phase 1/2 Study of Gene Therapy for CLN3 Batten Disease

2019-01-02 16:00:02 | How Are Sangamo Therapeutics’ Earnings and Expenses Trending?

2018-12-28 11:10:02 | A Financial Overview of Vanda Pharmaceuticals in December

2018-12-28 09:35:48 | Vanda Pharmaceuticals: Recent Developments and Analyst Ratings

2018-12-20 07:00:00 | Amicus Therapeutics Announces First Patient Dosed in Phase 3 PROPEL Pivotal Study of AT-GAA in Patients with Pompe Disease

2018-12-19 16:01:00 | Amicus Therapeutics Announces Executive Team Updates

2018-12-12 10:58:41 | Should You Worry About Amicus Therapeutics, Inc.’s NASDAQ:FOLD CEO Pay?

2018-12-11 16:01:00 | Amicus Therapeutics Awarded United Kingdom Prix Galien Medal for Galafold® Migalastat

2018-12-11 07:05:00 | Today's Research Reports on Trending Tickers: EQT Corporation and Transocean Ltd.

2018-12-10 03:21:53 | Amicus Therapeutics, Inc. FOLD Hedge Funds Are Snapping Up

2018-12-04 07:35:00 | Consolidated Research: 2018 Summary Expectations for Xencor, Cyclacel Pharmaceuticals, Amicus Therapeutics, Take-Two Interactive Software, CSG Systems International, and Vonage — Fundamental Analysis, Key Performance Indications

2018-11-14 06:55:00 | Today's Research Reports on Trending Tickers: Amicus Therapeutics and FibroGen

2018-11-13 08:07:33 | Jazz Pharmaceuticals: Analysts’ View in November

2018-11-12 07:00:00 | Amicus Therapeutics to Present at the Credit Suisse 27th Annual Healthcare Conference

2018-11-05 13:25:37 | Edited Transcript of FOLD earnings conference call or presentation 5-Nov-18 1:30pm GMT

2018-11-05 08:45:01 | Amicus Therapeutics FOLD Reports Q3 Loss, Lags Revenue Estimates

2018-11-05 07:42:22 | Amicus Therapeutics: 3Q Earnings Snapshot

2018-11-05 07:00:00 | Amicus Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Updates

2018-10-29 08:00:00 | Today's Research Reports on Trending Tickers: Amicus Therapeutics and Geron

2018-10-29 07:00:00 | Amicus Therapeutics to Announce Third Quarter 2018 Financial Results on November 5, 2018

2018-10-25 09:25:00 | Recent Analysis Shows PennyMac Mortgage Investment Trust, Amicus Therapeutics, Children's Place, PLDT, NanoString Technologies, and Worthington Industries Market Influences — Renewed Outlook, Key Drivers of Growth

2018-10-22 13:56:07 | 5 Low-Priced Biotech Stocks to Take Advantage of the Market Rout